• GigaAI

  Participated · Series B · Apr 2026

  GigaAI (Jijia Vision) develops world models and embodied intelligence systems, publishing GigaWorld (GigaWorld-0, GigaWorld-Policy, GigaWorld-1) and GigaBrain series models and positioning them as core engines for physical AGI. The company has built Maker H01, a high-degree-of-freedom humanoid robot designed for dexterous operation and mobile interaction, and reports commercial implementation in automotive, 3C, warehousing, and home-service scenarios with a target delivery volume in the thousands this year. In autonomous driving the firm released DriveDreamer and related simulators that have served more than 30 leading automotive OEMs and autonomous driving companies. For content production it is developing the Yisu Engine, integrating ultra-long-duration video generation, a real-time 3D world model framework, and 3D human generation tools. GigaAI reports building an industry-leading data base, projecting over 1 million hours of high-quality visual-action data and more than 10 million hours of pre-training data this year. The company was founded in June 2023 and is led by post-90s Tsinghua-educated founder Huang Guan, whose team has achieved top benchmark results (e.g., WorldArena) against major international institutions.

• Neurophth Therapeutics

  Led · Series C · Aug 2023

  Neurophth Therapeutics develops AAV-based gene therapies for ophthalmic diseases, including advanced investigational programs such as NR082 for ND4-LHON. Its AAV platform has been validated by data from an investigator-initiated retinal gene therapy study. NR082 has received orphan drug designation from both the U.S. FDA and the EMA. The company’s pipeline also includes programs for autosomal dominant optic atrophy, optic neuroprotection, vascular retinopathy and other preclinical candidates. Neurophth has subsidiaries in China (Wuhan, Shanghai and Suzhou) and the U.S. (San Diego, CA) and is led by founder, chairman and CEO Bin Li. The firm intends to use the new proceeds to accelerate clinical trials, enhance R&D capabilities and expand its pipeline. Neurophth Therapeutics develops gene therapies targeting ophthalmic diseases, with its lead investigational candidate NR082 (NFS-01, rAAV2-ND4) for ND4-mediated LHON. NR082 has orphan drug designation from the U.S. FDA and its IND for a Phase 1/2/3 trial was approved by China NMPA in March 2021, with the first patient dosed in June 2021. The company’s pipeline includes ND1-mediated LHON, autosomal dominant optic atrophy, optic neuroprotection (e.g., glaucoma), vascular retinopathy (e.g., diabetic retinopathy) and five other preclinical candidates. Neurophth has initiated scale-up of in-house manufacturing using single-use technologies at its Suzhou facilities to support future commercial demand. The company intends to use newly raised capital to accelerate growth, advance its lead LHON program ex-China, enrich its R&D pipeline through business development, and continue expanding its international-standard gene therapy manufacturing platform. Neurophth is a fully integrated genetic medicines company focused on AAV-delivered gene therapies for ocular diseases. Its lead investigational candidate is NR082 (rAAV2-ND4) for ND4-mediated Leber hereditary optic neuropathy (LHON), which received U.S. FDA orphan designation in Q3 2020. The company expects to advance NR082 toward IND submission and to initiate clinical trials in the first half of 2021. Neurophth is developing a pipeline of 10 gene therapy product candidates addressing both rare and common ocular diseases, including ND1-mediated LHON, autosomal dominant optic atrophy, glaucoma, and diabetic macular edema. It is building a commercially scalable GMP manufacturing facility in Suzhou and scaling up in-house manufacturing using single-use technologies, and plans to establish translational research centers. Headquartered in Wuhan with subsidiaries in Shanghai, Suzhou, and the US, Neurophth closed a Series A in early 2020 to initiate facility construction and accelerate nonclinical studies.

No current team members are available.